Skip to main content
. 2011 Dec 9;6(12):e28938. doi: 10.1371/journal.pone.0028938

Figure 1. CSF changes in 3 neurodegeneration biomarkers after aneurysm rupture.

Figure 1

(A) Western blot analyses of 14-3-3β, a calpain-cleaved α-spectrin COOH-terminal fragment (CCSctf), and UCH-L1 in 3 aSAH cases at the indicated times post-rupture (in days). Case 25 is representative of the subset of aSAH patients exhibiting large elevations in every neurodegeneration biomarker. Case 9, in contrast, shows a delayed increased in neurodegeneration biomarkers starting on day 5 after aneurysm rupture. Case 19 is representative of the subset of aSAH cases exhibiting consistently low or undetectable biomarker levels over the entire 10 day post-rupture period. (B) Western blot analysis of CCSctf levels 5 days post-rupture for 13 aSAH cases. Quantitative analysis (see Methods) showed that CSF levels of this biomarker vary by 100-fold across patients.